Accelerate to discover

Back to filter

Related topics

Early immune response in mice immunized with inactivated vaccine against SARS-CoV-2

Cytek Biosciences

Nov 19, 2020

The development of a vaccine against COVID-19 is a hot topic for many research laboratories all over the world. Our aim...

Bruker announces software provider PMOD Technologies LLC

Bruker Biospin

Nov 13, 2020

PMOD Technologies aims to equip researchers with best-in-class software tools for biomedical imaging research in humans...

Microvascular injury in mild traumatic brain injury accelerates alzheimer-like pathogenesis in mice

RWD

Nov 9, 2020

Traumatic brain injury (TBI) is considered as the most robust environmental risk factor for Alzheimer’s disease (AD)....

Discover the new NovoCyte Penteon - when exceptional performance meets simplicity

Agilent technologies

Nov 6, 2020

The NovoCyte Penteon flow cytometer builds on its successful predecessor, the NovoCyte. You now have the flexibility to...

Nov 23, 2020

CS-FNX Hitachi Koki, discover the state-of-art ultracentrifuges series

Hitachi Koki

Nov 4, 2020

Hitachi Koki, as a world leading producer of centrifuges offers general purpose floor standing and table top...

Curiox webinar - how to retain more cells for Single Cell Sequencing and proteogenomics ?

Curiox

Oct 28, 2020

Do you think that centrifuging cells at 500 x g is not going to cause issues? Moreover, sample prep involving...

Live animal imaging - Humane animal research

Bruker Biospin

Oct 26, 2020

Drawing on over 50 years of expertise in the life and animal sciences, Bruker designs preclinical imaging systems that...

Nov 23, 2020

3D time lapse imaging and quantitative analysis of multilayered Endothelial cells migration

Yokogawa

Oct 22, 2020

Time lapse confocal imaging has been an essential method to investigate the 3D dynamic behaviors of cells in tissue...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey